Multicenter, Open-label Study of Safety and Efficacy of Quisinostat in Combination With Paclitaxel + Carboplatin Chemotherapy in Patients With Metastatic or Locally Advanced Epithelial Ovarian Cancer, Primarily Peritoneal or Fallopian Tube Carcinoma, Resistant to First Line Platinum and Paclitaxel Based Chemotherapy
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Quisinostat (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors NewVac
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.
- 26 Jun 2017 Results from this study published in a NewVac Media Release.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.